Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2688462 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3217503 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3217491 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL2697951 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3214768 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3214782 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3217495 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3220475 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3220463 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL2688465 | 1.00 | S1PR2 (0.55) | S1PR2S1PR4S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123670-A1 | FIRE ANT BAITS WITH ENHANCED SELECTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2024-06-13 | — | — | WO | claimed |
| US-20240180149-A1 | FIRE ANT BAITS WITH ENHANCED SELECTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2024-06-06 | — | — | US | claimed |
| US-9943554-B2 | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | claimed |
| US-20160317588-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | SYNAPSIN PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | claimed |
| CN-101594867-B | The compositions relevant to fiery ant toxin, and they purposes in preparation treatment nervous system disorders and raising cognition and physical ability medicine | 辛纳普辛制药有限公司 | 2016-08-10 | — | — | CN | claimed |
| US-9259419-B2 | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | claimed |
| EP-2043642-B1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS INC (US) | 2015-03-25 | — | — | EP | claimed |
| US-20140086998-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | claimed |
| US-20100056572-A1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | claimed |
| CN-101594867-A | Compositions and the method relevant, and their purposes in treatment nervous system disorders and raising physical ability with fiery ant toxin | SYNAPSIN PHARMACEUTICALS INC (US) | 2009-12-02 | — | — | CN | claimed |
| EP-2043642-A2 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | Synapsin Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008008720-A2 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2024123670-A1 | FIRE ANT BAITS WITH ENHANCED SELECTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240180149-A1 | FIRE ANT BAITS WITH ENHANCED SELECTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2024-06-06 | — | — | US | disclosed |
| US-9943554-B2 | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160317588-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | SYNAPSIN PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20100056572-A1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| CN-101594867-A | Compositions and the method relevant, and their purposes in treatment nervous system disorders and raising physical ability with fiery ant toxin | SYNAPSIN PHARMACEUTICALS INC (US) | 2009-12-02 | — | — | CN | disclosed |
| EP-2043642-A2 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | Synapsin Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008720-A2 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056572-A1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | ACHE, SMN1; SMN2, NLN | S1PR2 732/4885S1PR4 953/4885S1PR1 594/4885 |
| US-20160317588-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | ACHE, SMN1; SMN2, NLN | S1PR2 732/4885S1PR4 953/4885S1PR1 594/4885 |
| US-20140086998-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | ACHE, SMN1; SMN2, NLN | S1PR2 732/4885S1PR4 953/4885S1PR1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.